港股创新药概念回调，恒生创新药ETF（159316）半日获3700万份净申购

Core Insights - The overall performance of various pharmaceutical and biotechnology indices showed mixed results, with the China Securities Innovation Drug Industry Index rising by 0.1% and the Hang Seng Hong Kong Stock Connect Innovation Drug Index declining by 0.6% [1][4]. Index Performance - The China Securities Biotechnology Theme Index decreased by 0.1%, while the Shanghai-Shenzhen 300 Pharmaceutical and Health Index remained stable with a 0.03% increase [1][4]. - The rolling price-to-earnings (P/E) ratio for the Shanghai-Shenzhen 300 Pharmaceutical and Health Index is currently at 30.0 times, with a valuation percentile of 41.0% [4][5]. - The China Securities Biotechnology Theme Index has a rolling P/E ratio of 53.3 times and a valuation percentile of 61.3% [4][5]. ETF Activity - The Hang Seng Innovation Drug ETF (159316) saw a net subscription of 37 million units, doubling its size to 1.08 billion yuan compared to a month ago [1].